Renaud Mazeron1, Pierre Maroun2, Pauline Castelnau-Marchand2, Isabelle Dumas3, Eleonor Rivin del Campo2, Kim Cao2, Andrea Slocker-Escarpa2, Rodrigue M'Bagui2, Florent Martinetti3, Anne Tailleur2, Alain Guemnie-Tafo3, Philippe Morice4, Cyrus Chargari5, Dimitri Lefkopoulos6, Christine Haie-Meder2. 1. Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Molecular Radiotherapy, INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France. Electronic address: Renaud.mazeron@gustaveroussy.fr. 2. Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France. 3. Medical Physics, Gustave Roussy Cancer Campus, Villejuif, France. 4. Gynecologic Surgery, Gustave Roussy Cancer Campus, Villejuif, France. 5. Radiation Oncology, Gustave Roussy Cancer Campus, Villejuif, France; Molecular Radiotherapy, INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France. 6. Molecular Radiotherapy, INSERM 1030, Gustave Roussy Cancer Campus, Villejuif, France; Medical Physics, Gustave Roussy Cancer Campus, Villejuif, France.
Abstract
PURPOSE: To establish dose-volume effect correlations for late bladder and rectum side effects in patients treated for locally advanced cervical cancer with concomitant chemoradiation followed by pulsed-dose rate image-guided adaptive brachytherapy. MATERIAL AND METHODS: The dosimetric data, converted in 2 Gy equivalent, from 217 patients were confronted to late morbidity defined as any event lasting or occurring 90 days after treatment initiation. Toxicity was assessed using the CTC-AE 3.0. Probit analyses and Log rank tests were performed to assess relationships. RESULTS: One hundred and sixty-one urinary and 58 rectal events were reported, affecting 98 (45.1%) and 51 (23.5%) patients, respectively. Cumulative incidences for grade 2-4 bladder and rectal morbidity were 24.3% and 9.6% at 3 years, respectively. Significant relationships were observed between grade 2-4 and 3-4 events and D0.1cm(3) and D2 cm(3) for the bladder and between grade 1-4 and 2-4 event probability and rectal D2 cm(3). The effective doses for 10% grade 2-4 morbidity were 65.3 Gy (59.8-81.3), and 55.4 Gy (15.7-63.6), respectively, for the rectum and bladder. Without considering urinary and rectal incontinence, for which the pertinence of correlating them with D2 cm(3) is questionable, ED10 were 68.5 Gy (62.9-110.6) and 65.5 Gy (51.4-71.6 Gy). When sorting patients according to D2 cm(3) levels, patients with high D2 cm(3) had significantly lower morbidity free survival rates for grade 1-4 and 2-4 urinary and rectal morbidity. CONCLUSION: Significant dose-volume effect relationships were demonstrated between the modern dosimetric parameters and the occurrence of late rectal and urinary morbidity in patients treated with pulsed-dose-rate brachytherapy. Further studies are required to refine these relationships according to clinical cofactors, such as comorbidities.
PURPOSE: To establish dose-volume effect correlations for late bladder and rectum side effects in patients treated for locally advanced cervical cancer with concomitant chemoradiation followed by pulsed-dose rate image-guided adaptive brachytherapy. MATERIAL AND METHODS: The dosimetric data, converted in 2 Gy equivalent, from 217 patients were confronted to late morbidity defined as any event lasting or occurring 90 days after treatment initiation. Toxicity was assessed using the CTC-AE 3.0. Probit analyses and Log rank tests were performed to assess relationships. RESULTS: One hundred and sixty-one urinary and 58 rectal events were reported, affecting 98 (45.1%) and 51 (23.5%) patients, respectively. Cumulative incidences for grade 2-4 bladder and rectal morbidity were 24.3% and 9.6% at 3 years, respectively. Significant relationships were observed between grade 2-4 and 3-4 events and D0.1cm(3) and D2 cm(3) for the bladder and between grade 1-4 and 2-4 event probability and rectal D2 cm(3). The effective doses for 10% grade 2-4 morbidity were 65.3 Gy (59.8-81.3), and 55.4 Gy (15.7-63.6), respectively, for the rectum and bladder. Without considering urinary and rectal incontinence, for which the pertinence of correlating them with D2 cm(3) is questionable, ED10 were 68.5 Gy (62.9-110.6) and 65.5 Gy (51.4-71.6 Gy). When sorting patients according to D2 cm(3) levels, patients with high D2 cm(3) had significantly lower morbidity free survival rates for grade 1-4 and 2-4 urinary and rectal morbidity. CONCLUSION: Significant dose-volume effect relationships were demonstrated between the modern dosimetric parameters and the occurrence of late rectal and urinary morbidity in patients treated with pulsed-dose-rate brachytherapy. Further studies are required to refine these relationships according to clinical cofactors, such as comorbidities.
Authors: Matthias M Manuel; Linda P Cho; Paul J Catalano; Antonio L Damato; David T Miyamoto; Clare M Tempany; Ehud J Schmidt; Akila N Viswanathan Journal: Radiother Oncol Date: 2016-06-16 Impact factor: 6.280
Authors: Sophia C Kamran; Matthias M Manuel; Paul Catalano; Linda Cho; Antonio L Damato; Larissa J Lee; Ehud J Schmidt; Akila N Viswanathan Journal: Brachytherapy Date: 2017-08-17 Impact factor: 2.362
Authors: Richard Pötter; Kari Tanderup; Christian Kirisits; Astrid de Leeuw; Kathrin Kirchheiner; Remi Nout; Li Tee Tan; Christine Haie-Meder; Umesh Mahantshetty; Barbara Segedin; Peter Hoskin; Kjersti Bruheim; Bhavana Rai; Fleur Huang; Erik Van Limbergen; Max Schmid; Nicole Nesvacil; Alina Sturdza; Lars Fokdal; Nina Boje Kibsgaard Jensen; Dietmar Georg; Marianne Assenholt; Yvette Seppenwoolde; Christel Nomden; Israel Fortin; Supriya Chopra; Uulke van der Heide; Tamara Rumpold; Jacob Christian Lindegaard; Ina Jürgenliemk-Schulz Journal: Clin Transl Radiat Oncol Date: 2018-01-11
Authors: Sati Akbaba; Jan Tobias Oelmann-Avendano; Tilman Bostel; Harald Rief; Nils Henrik Nicolay; Juergen Debus; Katja Lindel; Robert Foerster Journal: Radiol Oncol Date: 2018-09-11 Impact factor: 2.991
Authors: J Crezee; C M van Leeuwen; A L Oei; L E van Heerden; A Bel; L J A Stalpers; P Ghadjar; N A P Franken; H P Kok Journal: Radiat Oncol Date: 2016-02-02 Impact factor: 3.481
Authors: Peter de Boer; Agustinus J A J van de Schoot; Henrike Westerveld; Mark Smit; Marrije R Buist; Arjan Bel; Coen R N Rasch; Lukas J A Stalpers Journal: Strahlenther Onkol Date: 2017-11-03 Impact factor: 3.621